Biotech Values

[mcbio]

FWIW they look very good in the patients who are both high G and TN. And I would guess that the effect actually gets better in OS than in PFS, since even though they allowed xover the OS results and the PFS results were comparable. I'd guess that that is probably a significant part of the explanation as to why they chose OS as the primary endpoint in the ph iii.

Stat sig on OS in high G/TN in study not powered for it. Results look good to me. Anxious to see how the market responds on Monday.